Good Company

Dechra Agrees to Buy Gallant as the First Off-the-Shelf Stem Cell Therapy for Pets Nears an FDA Decision

San Diego's Gallant brings a GMP plant, a first-of-its-kind cold chain and a pipeline led by sonruvetcel for cats to Dechra's specialty care push, on confidential terms.

By Good Company Editorial Desk

Gallant logo

The News

Dechra has signed an agreement to acquire Gallant, the San Diego biotechnology company building off-the-shelf stem cell therapies for dogs and cats, the companies announced on November 9, 2026. Gallant describes itself as pioneering off-the-shelf mesenchymal stromal cell, or MSC, therapies for pets. Dechra called the deal complementary and aligned with its strategy to serve unmet needs in specialty care.

The parties agreed that the financial terms will remain confidential. Completion remains subject to customary closing conditions, and neither company gave an expected closing date or a detailed integration plan.

What Dechra is buying is not a marketed product. It is a platform, a pipeline and the operation behind them. Gallant was founded in 2018 and operates a San Diego manufacturing facility that the company describes as compliant with Good Manufacturing Practices, or GMP, standards. Its therapies are donor-derived, ready to use and given intravenously, with no tissue harvest from the patient. All are still investigational and unavailable for general use outside clinical trials.

The pipeline covers four areas: refractory feline chronic gingivostomatitis, a painful oral disease in cats; osteoarthritis in dogs and cats; feline chronic kidney disease; and canine atopic dermatitis. The lead program is sonruvetcel, for cats with refractory feline chronic gingivostomatitis, or FCGS.

Why It Matters

This deal lands as Gallant's lead product moves from promising science toward a regulatory decision. That timing is the story.

For sonruvetcel, the Food and Drug Administration's Center for Veterinary Medicine has already issued technical section complete letters for two key parts of its conditional approval file: Reasonable Expectation of Effectiveness in September 2025, and Target Animal Safety, covering a 365-day safety requirement, in November 2025. In the pivotal field study published in the Journal of Feline Medicine and Surgery, more than 75 percent of treated cats showed a clinically relevant improvement in quality of life by day 90, nearly half showed measurable improvement in oral lesions, and none had a serious treatment-related adverse event. Gallant says that, if conditionally approved, sonruvetcel would be the first FDA-labelled, off-the-shelf stem cell therapy in veterinary medicine.

Buying now, before that decision, is a bet on a new treatment modality, not on current revenue. It also fits a pattern Dechra has already set. In 2024 Dechra agreed to acquire Boston-based Invetx, a developer of monoclonal antibody therapeutics for companion animals, for up to $520 million. Invetx gave Dechra one kind of biologic, long-acting antibodies for chronic diseases including osteoarthritis and atopic dermatitis. Gallant gives it a second, entirely different kind: living cells for many of the same disease areas.

Gallant has also done commercial groundwork a buyer would otherwise have to build. In February 2026 it signed a fulfillment agreement with MWI Animal Health, part of Cencora, to create what the companies called the first ultra-low temperature cold chain in veterinary medicine. Sonruvetcel must be stored at minus 80 degrees Celsius. MWI agreed to ship it overnight from Edwardsville, Kansas, covering the continental United States and Alaska, Hawaii and Puerto Rico.

The Numbers

  • Deal terms: confidential, by agreement of both parties. No price or closing date was disclosed in the November 9 announcement.
  • Founded: 2018, in San Diego, California, with a GMP-compliant manufacturing facility there, the company says.
  • Last disclosed financing: an $18 million Series B closed June 30, 2025, led by Digitalis Ventures, with BOLD Capital, Hill Creek Partners and new investor NovaQuest Capital Management. That round does not establish the acquisition price.
  • Lead study: 46 cats with refractory FCGS. More than 75 percent of treated cats improved on quality of life by day 90, nearly half improved on oral lesions, and there were no serious treatment-related adverse events, the company reported.
  • Feline osteoarthritis pilot: 35 client-owned cats across 6 U.S. clinics, randomized, masked and placebo-controlled. At day 90, 76.2 percent of treated cats met the improvement threshold, compared with 36.4 percent on placebo.
  • Canine osteoarthritis pilot: 88 client-owned dogs, randomized and placebo-controlled, reported May 6, 2026, with 2 doses 14 days apart and follow-up through day 90. Both osteoarthritis programs have eligibility for the FDA expanded conditional approval pathway, with a 2028 target for the canine program, the company says.
  • Clinic readiness survey: 1,095 U.S. small animal professionals, surveyed with the American Animal Hospital Association. Nearly 90 percent agreed current therapies mainly manage symptoms, 95 percent said stem cell therapy would become part of standard care within a decade, and 93 percent said they would be more likely to offer it if available off the shelf by intravenous protocol.
  • Cold chain: storage at minus 80 degrees Celsius, overnight shipping from MWI's Edwardsville, Kansas center.
  • Dechra's prior biologics bet: up to $520 million for Invetx in 2024, cash-free and debt-free, according to the Invetx announcement.

What It Means For You

If you run a specialty or referral practice, start treating cell therapy as a category to learn, not a curiosity to watch. The practical questions are concrete: which patients fit, how a frozen product is ordered, stored and thawed, who handles it, and how you explain an investigational therapy honestly to a client whose cat has run out of options for a painful mouth. The clinics that understand the protocol before a launch will not be learning it while a client is waiting.

If you lead a smaller animal health company, notice what made Gallant acquirable before it had an approved product. It was not one study. It was a stack: a lead indication with few good alternatives, completed regulatory sections, a manufacturing plant it controlled, a distribution partner willing to build new infrastructure, and a pipeline that reused the same platform across four diseases. Buyers pay for that stack because it lowers more than one kind of risk at once. Audit your own stack that way and close the weakest layer first.

If you are a marketer, hold your language to the regulatory facts. These therapies are investigational. Pathway eligibility is not approval, and a pilot result is not a label claim. Copy that blurs that line will create trust and compliance problems.

What To Watch

First, closing. The agreement is signed, but completion depends on customary closing conditions, and no date has been given.

Second, the FDA decision on sonruvetcel. The effectiveness and safety sections are complete, but conditional approval has not been granted, and Gallant had previously targeted early 2026 before the timeline moved later. The decision, and its label, will set the commercial ceiling for everything behind it.

Third, whether the cold chain works at clinic scale. A minus 80 degree product shipped overnight from Kansas is a new operating model for ordinary practices. Adoption will depend as much on reliability, handling and cost as on the biology.

Fourth, what Dechra says about the team and the San Diego site after closing. Chief executive Dr. Linda Black, a veterinarian with a PhD in cell and molecular biology, joined the founding team in 2019 and became chief executive in April 2021. In cell therapy, the people who make the product are a large part of what was bought. Watch whether they stay, and whether Dechra funds the other programs at Gallant's planned pace.

Sources

  • Gallant, Gallant Announces Agreement to Be Acquired by Dechra, November 9, 2026: https://www.gallant.com/news/gallant-announces-agreement-to-be-acquired-by-dechra/
  • DevCuration, Dechra Agrees to Acquire Gallant's Cell-Therapy Platform, November 10, 2026: https://devcuration.com/articles/dechra-gallant-acquisition-cell-therapies
  • Dealroom News, Dechra buys pet stem-cell developer Gallant as FDA decision nears, November 10, 2026: https://dealroom.co/news/171055-dechra-buys-pet-stem-cell-developer-gallant-as-fda-decision-nears/
  • Gallant via dvm360, Gallant Achieves FDA Safety Milestone for Stem Cell Therapy (sonruvetcel technical sections and 46-cat study): https://www.gallant.com/news/fda-completes-safety-for-gallants-first-ready-to-use-stem-cell-therapy-for-refractory-fcgs/
  • dvm360, Ready-to-use feline OA stem cell therapy gains entry to FDA's faster conditional approval pathway, April 15, 2026: https://www.dvm360.com/view/ready-to-use-feline-oa-stem-cell-therapy-gains-entry-to-fda-s-faster-conditional-approval-pathway
  • Gallant, Gallant and MWI Animal Health partnership to deliver stem cell therapy into veterinary clinics, February 27, 2026: https://www.gallant.com/news/gallant-announces-first-of-its-kind-partnership-with-mwi-animal-health-to-deliver-anticipated-fda-conditionally-approved-stem-cell-therapy-into-veterinary-clinics/
  • Gallant, Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market, June 30, 2025: https://www.novaquest.com/news/gallant-closes-18-million-series-b-to-bring-ready-to-use-stem-cell-therapies-for-pets-to-market/
  • Business Wire, Invetx Announces Upcoming Acquisition by Dechra Pharmaceuticals, July 18, 2024: https://www.businesswire.com/news/home/20240718774207/en/Invetx-Announces-Upcoming-Acquisition-by-Dechra-Pharmaceuticals-Global-Leader-in-Animal-Health